Wave Life Sciences Press Release and Community Letter

In December 2022, Wave Life Sciences announced a positive update from the initial cohort of the Phase 1b/2a study of WVE-N531 in three boys with Duchenne muscular dystrophy (DMD) amenable to exon 53 skipping. They are encouraged by these early results and what they may mean for WVE-N531’s potential to restore meaningful levels of dystrophin with continued dosing.
Read the below press release and letter to the community:

Related Posts

Share This Page

Make an Impact

You can advance the care, treatment and cure for Duchenne muscular dystrophy. Contributions in any amount can truly make a difference and can be credited to a fundraiser or event from the list below.